Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atyr Pharma Inc Cmn (LIFE) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 59,300
  • Shares Outstanding, K 23,720
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,970 K
  • 36-Month Beta 3.19
  • Price/Sales N/A
  • Price/Book 0.80

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +54.76%
on 12/21/16
3.45 -5.80%
on 01/18/17
+0.85 (+35.42%)
since 12/16/16
3-Month
2.10 +54.76%
on 12/21/16
3.80 -14.47%
on 11/21/16
+0.50 (+18.18%)
since 10/18/16
52-Week
2.10 +54.76%
on 12/21/16
6.81 -52.28%
on 01/27/16
-2.69 (-45.29%)
since 01/15/16

Most Recent Stories

More News
Roberts recuses from patent case after discovering conflict

WASHINGTON (AP) — Supreme Court Chief Justice John Roberts says he will no longer participate in deciding a patent infringement case because he discovered he owns shares in the parent company of one...

aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris(TM) in Exploratory Trials

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced clinical results...

aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that senior management...

aTyr Pharma Enters into $20 Million Credit Facility

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced it has entered into...

aTyr Pharma (LIFE) Looks Good: Stock Adds 5.9% in Session

aTyr Pharma Inc. (LIFE) saw its shares rise almost 6% in the last trading session.

aTyr Pharma Announces Third Quarter 2016 Operating Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced operating results...

aTyr Pharma to Present at Three Upcoming Conferences in November

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced its participation...

aTyr Pharma Receives FDA Fast Track Designation for Resolaris(TM) to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product...

aTyr Pharma Presents Additional Data for Resolaris(TM) Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society

aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were presented at the 21st International Congress of the World...

Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

See More

Support & Resistance

2nd Resistance Point 3.88
1st Resistance Point 3.57
Last Price 3.25
1st Support Level 2.82
2nd Support Level 2.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.